Trial Profile

Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enavogliflozin (Primary) ; Gemigliptin (Primary) ; Metformin (Primary)
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms ENHANCE-M
Sponsors Daewoong Pharmaceutical

01 Nov 2022 According to a Daewon Pharmaceutical media release, data presented at the 2022 International Congress of Diabetes and Metabolism (2022 ICDM).
23 Oct 2022 Status changed from recruiting to completed.
25 Jan 2022 Results presented in a Daewoong Pharmaceutical media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com